Press "Enter" to skip to content

U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million

Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back.

Original source: http://feeds.reuters.com/~r/reuters/INhealth/~3/oSONwRVEQdA/u-s-benefits-manager-baulks-after-novartis-values-gene-therapy-at-4-5-million-idINKCN1NS0CX

Also Read:   Apple Watch detects irregular heart beat in large U.S. study